Pharmaceuticals

SHINEWAY PHARM

SHINEWAY PHARM released FY2025 9 Months earnings on March 27, 2026 (BJT), actual revenue HKD 2.6 B, actual EPS HKD 1.1196

SHINEWAY PHARM released FY2025 Q3 earnings on March 27, 2026 (BJT) with actual revenue of HKD 810.43 M and EPS of HKD 0.2435

SHINEWAY PHARM released FY2025 Q4 earnings on March 27 Pre-Market (BJT), actual revenue HKD 824.42 M, actual EPS HKD 0.2467

SHINEWAY PHARM released FY2025 earnings on March 27 Pre-Market (BJT), actual revenue HKD 3.427 B (forecast HKD 3.546 B), actual EPS HKD 1.3744 (forecast HKD 1.2221)

SHINEWAY PHARM to Release FY2025 Earnings on March 27 Pre-Market (BJT), Forecast Revenue HKD 3.471 B, EPS HKD 1.1961

Guoyuan International Publishes Report on Shenwei Pharmaceutical's Smooth Progress in Traditional Chinese Medicine Innovation

SHINEWAY PHARM released FY2025 Q1 earnings on August 27, 2025 (BJT) with actual revenue of HKD 885 M and EPS of HKD 0.4337

SHINEWAY PHARM released FY2025 Semi-Annual earnings on August 27 Pre-Market (BJT), actual revenue HKD 1.789 B, actual EPS HKD 0.877

SHINEWAY PHARM released FY2025 Q2 earnings on August 27 Pre-Market (BJT), actual revenue HKD 904.46 M, actual EPS HKD 0.4432

SHINEWAY PHARM to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

Shenwei Pharmaceutical Receives A Rating in Huazheng Index ESG Assessment

Sinovate Pharmaceutical Q1 2025 Revenue Down 31.9%

Shenwei Pharmaceutical Receives A Rating in Huazheng Index 2025 ESG Rating, Ranked 14th

SHINEWAY PHARM released FY2024 Q3 earnings on March 28 (BJT), actual revenue HKD 937.38 M (forecast HKD 860.35 M), actual EPS HKD 0.1551

SHINEWAY PHARM released FY2024 9 Months Earnings on March 28, 2025 (BJT) with actual revenue of HKD 3.189 B and EPS of HKD 1.0513

SHINEWAY PHARM released FY2024 Q4 earnings on March 28 After-Market (BJT), actual revenue HKD 899.67 M (forecast HKD 856.4 M), actual EPS HKD 0.1489

SHINEWAY PHARM released FY2024 earnings on March 28 After-Market (BJT), actual revenue HKD 4.09 B (forecast HKD 4.311 B), actual EPS HKD 1.2015 (forecast HKD 1.3315)

Shenwei Pharmaceutical Releases 2024 Annual Results, Revenue Decreases by 16.35% Year-on-Year

SHINEWAY PHARM to release FY2024 earnings on March 28 During-Market BJT, forecast revenue 4.335 B HKD, EPS 1.3387 HKD

Daiwa Capital Markets Downgrades China Shenwei Pharmaceutical to Hold

JIAODA WITHUB

TIMELESS

CHI HO DEV

BAIJIN LIFE SCI

SCIENTECH

OKG TECH

WECON HOLDINGS

NEW GONOW RV

REPUBLIC HC

MAN YUE TECH

02877

China Shineway Pharmaceutical Group Limited has scheduled its annual general meeting for May 28, 2026, in Hong Kong. Shareholders will review the audited financial statements for the year ended December 31, 2025, and vote on the re-election of three directors, directors’ remuneration, and the re-appointment of Deloitte as auditor. The agenda includes authorizing the board to issue new shares up to 20% of the company’s issued share capital, enhancing financial flexibility and potential funding capacity. This move aims to maintain governance continuity and readiness for growth in the competitive pharmaceutical sector.

Tip Ranks

China Shineway Pharma Sets 2026 AGM to Approve Results and Share Issuance Mandate

159929

512290

589720

512010

159992

SXTC

510660

588130

China Shineway Pharmaceutical Declares First Interim Dividend for Fiscal 2026

China Universal 800 Health Care ETF

Guotai CSI Bio-medicine ETF

Guotai SSE STAR Brand Name Drug ETF

E Fund CSI 300 Health Care ETF

Yinhua CSI Innovative Drugs Industry ETF

China SXT Pharmaceuticals

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC SSE STAR Biology and Medicine ETF

China Shineway Pharmaceutical Declares First Interim Dividend for Fiscal 2026

513120

159316

Shineway Profit Rises Despite Revenue Slump as TCM Sector Resets

Bosera Hang Seng Health Care ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Hinova

SINOPHARM(CNCM LTD)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Shineway Profit Rises Despite Revenue Slump as TCM Sector Resets

In a report released yesterday, from Guoyuan Securities (HK) maintained a Buy rating on China Shineway Pharmaceutical Group Limited, with a price target of HK$10.04.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential The analyst consensus on China Shineway Pharmaceutical Group Limited is currently a Hold rating.

China Shineway Pharmaceutical Group Limited (2877) Receives a Buy from Guoyuan Securities (HK)

01209

601857

00857

01617

02020

HSAI

The Hong Kong stock investment log for September 9, 2025, shows that Hesai-W is in the process of an IPO, and several companies such as Jiujiang Bank and NANFANG COMM will hold shareholder meetings. Additionally, several companies including CHINA RES MIXC and SHINEWAY PHARM will distribute dividends, with ex-dividend dates also involving multiple companies, including PETROCHINA and ANTA SPORTS

Zhitong

CHINA RES MIXC

PETROCHINA

NANFANG COMM

ANTA SPORTS

Hesai

Zhitong Hong Kong Stock Investment Diary | September 9

SHINEWAY PHARM released its mid-term results for 2025, with revenue of 1.653 billion yuan, a year-on-year decrease of 20.8%; profit for the period was 615 million yuan, a year-on-year decrease of 1.89%. Basic earnings per share were 0.81 yuan, and an interim dividend of 0.11 yuan per share is proposed. The gross profit margin fell from 75.3% to 72.2%, mainly due to rising raw material costs. Despite the decline in sales and gross profit margin, net profit only slightly decreased by 1.9%, and the net profit margin rose to 37.2%. Oral products accounted for 65.8% of total sales

SHINEWAY PHARM released its interim results, with a profit of 615 million yuan, a year-on-year decrease of 1.89%

06911

00248

01786

00361

On August 27, 2025, the investment log of Hong Kong-listed companies is as follows: Category Company New Share Activities Aux Electric (in IPO) Earnings Announcement Date Times Fortune Investment Northeast Electric Dongguang Chemical CRCCE Kaisa Health Nayuki's Tea Baoli Holdings SINO GOLF HOLD China Oriental Education SHINEWAY PHARM Shareholders Meeting Date Kingsoft Technology Industrial Chenghui International Quantum Thinking LANCANG TEA Shenwan Hongyuan Hong Kong Huaxin Handbag International Holdings Hon Hai Group Holdings Yihui Group Changjiu Co., Ltd. HKC INT'L HOLD Dividend Distribution Chinese Estates Holdings (Ex-dividend date) Jereh International Holdings (Ex-dividend date) Hysan Development (Ex-dividend date) China Telecom (Ex-dividend date) MTR Corporation (Ex-dividend date) NetEase-S (Ex-dividend date) SF REIT (Ex-dividend date) China Everbright Water (Ex-dividend date) Biyuan (Ex-dividend date) Tai Hing Property (Ex-dividend date) Taobao (Dividend date) Taobao (Dividend date) Qin Port Co., Ltd. (Dividend date) Kangsheng Global (Dividend date) Agricultural Bank (Dividend date) Meidong Automobile (Dividend date) Nongfu Spring (Dividend date) China Coal Energy (Dividend date)

LANCANG TEA

HKC INT'L HOLD

CRCCE

HANFORT DEV H

Zhitong Hong Kong Stock Investment Log | August 27

According to the Zhitong Finance APP, SHINEWAY PHARM announced that independent non-executive director Wang Guihua has been appointed as a member of the company's nomination committee, effective from June 10, 2025

SHINEWAY PHARM: Wang Guihua has been appointed as a member of the Nomination Committee

SHINEWAY PHARM(02877.HK)

China Shineway Pharma Sets 2026 AGM to Approve Results and Share Issuance Mandate

China Shineway Pharmaceutical Declares First Interim Dividend for Fiscal 2026

Shineway Profit Rises Despite Revenue Slump as TCM Sector Resets

China Shineway Pharmaceutical Group Limited (2877) Receives a Buy from Guoyuan Securities (HK)

Zhitong Hong Kong Stock Investment Diary | September 9

SHINEWAY PHARM released its interim results, with a profit of 615 million yuan, a year-on-year decrease of 1.89%

Zhitong Hong Kong Stock Investment Log | August 27

SHINEWAY PHARM: Wang Guihua has been appointed as a member of the Nomination Committee